[Fidarestat (SNK-860)].
Hibi
Chihiro
C
Research & Development Division, Sanwa Kagaku Kenkyusho Co., Ltd.
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D000818:Animals; D017326:Clinical Trials, Phase III as Topic; D003929:Diabetic Neuropathies / Q000188:drug therapy / Q000503:physiopathology; D003930:Diabetic Retinopathy / Q000188:drug therapy / Q000209:etiology; D016228:Endothelial Growth Factors / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use; D048289:Imidazolidines; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism; D008222:Lymphokines / Q000378:metabolism; D009431:Neural Conduction / Q000187:drug effects; D009475:Neurons, Afferent / Q000502:physiology; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D007004:Hypoglycemic Agents; D007093:Imidazoles; D048289:Imidazolidines; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; C077139:fidarestat; D000449:Aldehyde Reductase